Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.9 Million SEK | -36.27% |
| 2022 | 7.69 Million SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 2 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q1 | 5.88 Million SEK | 0.0% |
| 2024 Q2 | 5.52 Million SEK | 0.0% |
| 2023 FY | 4.9 Million SEK | -36.27% |
| 2023 Q3 | 5.66 Million SEK | -9.4% |
| 2023 Q2 | 6.25 Million SEK | -8.51% |
| 2023 Q4 | 4.9 Million SEK | -13.41% |
| 2023 Q1 | 6.83 Million SEK | -11.2% |
| 2022 Q2 | 8.72 Million SEK | 36.96% |
| 2022 Q4 | 7.69 Million SEK | -6.95% |
| 2022 FY | 7.69 Million SEK | 0.0% |
| 2022 Q1 | 6.37 Million SEK | 0.0% |
| 2022 Q3 | 8.27 Million SEK | -5.19% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 2 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.663% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.663% |
| Arcoma AB | 1.92 Million SEK | -154.639% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 88.401% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.72% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 91.496% |
| CellaVision AB (publ) | 28.66 Million SEK | 82.881% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -2100.403% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -179.914% |
| Duearity AB (publ) | 2.94 Million SEK | -66.901% |
| Dignitana AB (publ) | 6.07 Million SEK | 19.255% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -113.343% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.874% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 22.762% |
| Integrum AB (publ) | 4.84 Million SEK | -1.287% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -2281.712% |
| Mentice AB (publ) | 2.14 Million SEK | -128.867% |
| OssDsign AB (publ) | 214 Thousand SEK | -2192.943% |
| Paxman AB (publ) | 2.53 Million SEK | -93.795% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -63.345% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -17.418% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 74.449% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -384.871% |
| Senzime AB (publ) | 8.57 Million SEK | 42.797% |
| SpectraCure AB (publ) | 4.39 Million SEK | -11.596% |
| Stille AB | 38.06 Million SEK | 87.109% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.738% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 76.82% |